drugset / Trial / NCT05379322
The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
SYBRA is an open-label, phase 3, randomized controlled clinical trial that aims to assess the use of synovial biopsies in predicting response to biologic therapy in patients with rheumatoid arthritis that have failed disease-modifying drugs. The project has the potential to help change the current practice by offering the best treatment option. The decision to choose the best treatment for a particular patient is especially important in the context of the growing number of therapies available as a first-line option and the lack of specific biomarkers to predict response to treatment.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
Outcome
Outcome not reported
Stopped: “Decision of the local healthcare authority”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | — | — |
| Subject | Baricitinib | Small molecule | — | — |
| Subject | Certolizumab | Protein / enzyme biologic | — | — |
| Subject | Etanercept | Protein / enzyme biologic | — | — |
| Subject | Golimumab | Monoclonal antibody | — | — |
| Subject | Tofacitinib | Small molecule | — | — |
| Subject | Upadacitinib | Small molecule | — | — |